HER2-Negative Breast Cancer Market Forecast and Insights: Exploring Growth Trends, Market Size, and Emerging Opportunities
2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!
How Are Key Drivers in the Industry Acting as Catalysts for the Growth of theHER2-Negative Breast Cancer Market?
The increasing incidence of breast cancer is expected to drive the growth of the HER2-negative breast cancer market in the coming years. Breast cancer is characterized by the uncontrolled growth of abnormal cells in the breast, often originating in the ducts or lobules. Contributing factors to the rising incidence of breast cancer include greater awareness and enhanced screening methods, which lead to earlier and more frequent detection. HER2-negative breast cancer plays a significant role in advancing research into breast cancer by providing insights into tumor biology and treatment strategies, thereby aiding the development of more targeted therapies. For example, the Centers for Disease Control and Prevention reported in June 2024 that in 2021, 272,454 new cases of breast cancer were diagnosed in U.S. females, and in 2022, 42,211 females died from the disease. Consequently, the growing incidence of breast cancer is driving the growth of the HER2-negative breast cancer market.
Get Your Free Sample Report Now – Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21203&type=smp
#What Growth Opportunities Will Drive the HER2-Negative Breast Cancer Market’s CAGR Through 2034?
The HER2-negative breast cancer market has grown strongly, rising from $16.29 billion in 2024 to $17.62 billion in 2025 at a CAGR of 8.1%. Key growth drivers include the increasing prevalence of breast cancer, heightened awareness, rising healthcare spending, an aging population, and improved healthcare infrastructure.
The HER2-negative breast cancer market size is expected to witness substantial growth in the coming years, reaching $23.86 billion by 2029 at a CAGR of 7.9%. The market expansion is driven by increased alcohol consumption, a growing trend of unhealthy lifestyles, rising obesity rates, a surge in tobacco usage, and an increasing demand for effective treatment solutions. Key trends anticipated include advancements in diagnostic technologies, integration of targeted therapies, growing adoption of immunotherapies, FDA approvals, and continuous technological advancements.
You can Directly Purchase the Report Here:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21203
What Are the Current Market Growth and Trends in theHER2-Negative Breast Cancer Market That Industry Players Should Watch?
In the HER2-negative breast cancer market, companies are focusing on securing regulatory approvals to expand their product portfolios and enhance their market presence. Regulatory approvals are granted by agencies like the FDA once a drug meets safety, efficacy, and quality standards. In October 2024, Genentech Inc., a US-based biotechnology corporation, received FDA approval for Itovebi (inavolisib), a targeted treatment for advanced hormone receptor-positive (HR+), HER2-negative breast cancer with a PIK3CA mutation. This approval allows Itovebi to be used in combination with palbociclib and fulvestrant, improving progression-free survival for patients compared to standard treatments.
What Are the Major Market Players Making an Impact on theHER2-Negative Breast Cancer Market Growth?
Major companies operating in the HER2-negative breast cancer market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bayer AG, Bristol-Myers Squibb Company, Sanofi S.A., AstraZeneca PLC, Novartis International AG, Eli Lilly and Company, Amgen Inc., Daiichi Sankyo Company Limited, Jiangsu Hansoh Pharmaceutical Co. Ltd., BeiGene Ltd., Chipscreen Biosciences Ltd., F. Hoffmann-La Roche Ltd, PharmAbcine Inc., Adagene Inc., H3 Biomedicine Inc., Radius Health Inc., Zenith Epigenetics Ltd.
Order Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/her2-negative-breast-cancer-global-market-report
How Are the Key Segments of the HER2-Negative Breast Cancer Market Driving Opportunities and Innovations?
The HER2-negative breast cancer market covered in this report is segmented –
1) By Treatment Type: Chemotherapy, Hormone Therapy, Targeted Therapy, Immunotherapy
2) By Cancer Stage: Early Stage, Locally Advanced Stage, Metastatic Stage
3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
Subsegments:
1) By Chemotherapy: Anthracyclines, Taxanes, Platinum-Based Chemotherapy, Alkylating Agents, Antimetabolites
2) By Hormone Therapy: Selective Estrogen Receptor Modulators (SERMs), Aromatase Inhibitors, Selective Estrogen Receptor Degraders (SERDs)
3) By Targeted Therapy: CDK4/6 Inhibitors, PI3K Inhibitors, PARP Inhibitors
4) By Immunotherapy: Immune Checkpoint Inhibitors, Tumor-Infiltrating Lymphocyte (TIL) Therapy
Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=21203&type=smp
What Regions Are At the Forefront of #How Are Key Drivers in the Industry Acting as Catalysts for the Growth of theHER2-Negative Breast Cancer Market?# Market Expansion?
North America was the largest region in the HER2-negative breast cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the HER2-negative breast cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Reports Similar to the Global HER2-Negative Breast Cancer Market 2025, By The Business Research Company:
Anemia and Other Blood Disorder Drugs Global Market Report 2025
Blood Cancer Drugs Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/blood-cancer-drugs-global-market-report
Lateral Flow Immunoassay (LFIA) Based Rapid Test Global Market Report 2025
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
